A genetic risk score to predict treatment nonresponse in psychotic depression

Autor: Sophie E. ter Hark, Marieke J. H. Coenen, Cornelis F. Vos, Rob E. Aarnoutse, Willem A. Nolen, Tom K. Birkenhager, Walter W. van den Broek, Arnt F. A. Schellekens, Robbert-Jan Verkes, Joost G. E. Janzing

Publikováno v: Translational Psychiatry, Vol 14, Iss 1, Pp 1-7 (2024)

Abstract Psychotic depression is a severe and difficult-to-treat subtype of major depressive disorder for which higher rates of treatment-resistant depression were found. Studies have been performed aiming to predict treatment-resistant depression or

Externí odkaz: https://doaj.org/article/ac4aa602dde14f3a878aafc65df64f6b

Cortical Inhibition and Plasticity in Major Depressive Disorder

Autor: Jesminne Castricum, Tom K. Birkenhager, Steven A. Kushner, Ype Elgersma, Joke H. M. Tulen

Publikováno v: Frontiers in Psychiatry, Vol 13 (2022)

BackgroundMajor depressive disorder (MDD) is a severe psychiatric disorder that is associated with various cognitive impairments, including learning and memory deficits. As synaptic plasticity is considered an important mechanism underlying learning

Externí odkaz: https://doaj.org/article/da770be0f5864ffe9ddb2d4cce41854b

Efficacy and safety of selegiline across different psychiatric disorders

Autor: Flavia Rossano, Claudio Caiazza, Andrea Sobrino, Niccolò Solini, Alessandro Vellucci, Nicolas Zotti, Michele Fornaro, Ken Gillman, Carlo Ignazio Cattaneo, Vincent Van den Eynde, Tom K. Birkenhager, Henricus G. Ruhé, Stephen Stahl, Felice Iasevoli, Andrea de Bartolomeis

Publikováno v: European Neuropsychopharmacology, 72, 60-78. Elsevier
European neuropsychopharmacology
Rossano, F, Caiazza, C, Sobrino, A, Solini, N, Vellucci, A, Zotti, N, Fornaro, M, Gillman, K, Cattaneo, C I, van den Eynde, V, Birkenhager, T K, Ruhé, H G, Stahl, S, Iasevoli, F & de Bartolomeis, A 2023, ' Efficacy and safety of selegiline across different psychiatric disorders : A systematic review and meta-analysis of oral and transdermal formulations ', European Neuropsychopharmacology, vol. 72, pp. 60-78 . https://doi.org/10.1016/j.euroneuro.2023.03.012
European Neuropsychopharmacology, 72, 60-78
European Neuropsychopharmacology, 72, pp. 60-78

Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) result-ing in non-selective MAOI activity at oral doses >20 mg/day. The pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::469fbb9eec6ee8b1011410740b411049
https://doi.org/10.1016/j.euroneuro.2023.03.012

Association of the neutrophil to lymphocyte ratio and white blood cell count with response to pharmacotherapy in unipolar psychotic depression: An exploratory analysis

Autor: Cornelis F. Vos, Tom K. Birkenhäger, Willem A. Nolen, Walter W. van den Broek, Marieke J.H. Coenen, Sophie E. ter Hark, Robbert-Jan Verkes, Joost G.E. Janzing

Publikováno v: Brain, Behavior, & Immunity - Health, Vol 16, Iss , Pp 100319- (2021)

Background: Low-grade inflammation occurs in a subgroup of patients with Major Depressive Disorder (MDD) and may be associated with response to antidepressant medications. The Neutrophil to Lymphocyte Ratio (NLR) and total White Blood cell Count (WBC

Externí odkaz: https://doaj.org/article/f5accf6f1dd04bf7bc9244d27fcedabb

Response after Infection-Associated Rise in Clozapine Levels in Treatment-Resistant Schizoaffective Disorder

Autor: Nina H. Grootendorst-van Mil, Anna R. M. Huiskens, Sieds Dieleman, Tom K. Birkenhäger

Publikováno v: Case Reports in Psychiatry, Vol 2018 (2018)

The clinical management of patients with treatment-resistant psychotic disorders is still challenging despite years of extensive research. If first-line antipsychotic treatment proves ineffective, clozapine is considered golden standard. Herein, we r

Externí odkaz: https://doaj.org/article/4dda49f0902744a78de6008b49d240e0